There wasn't enough patients in GVHD001 alone for 54 above and below the median data points to be put together. I recall that only about 25 of the 54 that were in the GVHD phase 3 trial had blood samples taken. I recall that some of the patients in the phase 3 trial had received product from multiple lots - using data from multiple lots would confound the analysis of patient survival measured against the product lot.
BTW. I mean you no disrespect, but my offer was specifically to LED. (to walk through the science) I have to protect my time. LED might teach me something (even as I try to show her) or not.
But most people that are frequent long term posters on this forum I already have a stereotype about and I don't feel equally inclined to make an effort for all of them.
Cell Therapy News/Articles, page-16591
-
- There are more pages in this discussion • 1,291 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.8¢ | 93.5¢ | $4.207M | 4.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 42268 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 48002 | 3 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |